Influenza D Virus Shows Alarming Potential for Human Spillover

For over a decade, influenza D virus (IDV) has circulated quietly among livestock, drawing little attention from public health experts. That changed in early 2026, when researchers at The Ohio State University uncovered compelling evidence that this little-known pathogen can efficiently replicate in human airway cells—a critical first step toward potential zoonotic transmission. The findings, published in a preprint study on bioRxiv, underscore an urgent need for expanded surveillance at the animal-human interface.

What Is Influenza D Virus?

First identified in 2011 in swine, IDV is one of four known influenza virus types, alongside the more familiar influenza A, B and C. Even as influenza A and B are responsible for seasonal flu epidemics in humans, IDV has primarily been detected in cattle, pigs, and other livestock. Until recently, its ability to infect humans remained largely theoretical.

The virus is distinct from its influenza cousins in several key ways:

• Host Range: IDV primarily infects cattle, with occasional detections in pigs, sheep, and goats. Unlike influenza A, it has not been widely associated with human illness—yet.
• Genetic Stability: IDV mutates more slowly than influenza A, which could make it easier to track and contain if spillover occurs.
• Transmission: While respiratory droplets are the primary route for most influenza viruses, IDV may also spread through indirect contact with contaminated surfaces or animal secretions.

The Breakthrough: Human Airway Replication

The Ohio State University study, led by researchers from the Department of Veterinary Biosciences and the Infectious Diseases Institute, provides the most detailed evidence to date of IDV’s compatibility with human biology. Using cultured human airway epithelial cells—considered the gold standard for modeling respiratory infections—the team demonstrated that IDV can:

• Attach to and enter human cells with efficiency comparable to human-adapted influenza viruses.
• Replicate robustly within 24 to 48 hours, producing viral loads similar to those seen in established human pathogens.
• Evade early immune responses, a trait that could facilitate sustained infection in a new host species.

“These findings are a wake-up call,” said Emily M. King, a co-author of the study and researcher at The Ohio State University. “While we haven’t seen widespread human cases of IDV, the virus’s ability to replicate in human tissue suggests it’s only a matter of time before we observe isolated spillover events—or worse.”

Why This Matters: The Zoonotic Threat

Zoonotic diseases—pathogens that jump from animals to humans—account for 60% of all infectious diseases in humans and 75% of emerging infectious diseases. The COVID-19 pandemic, caused by the zoonotic SARS-CoV-2 virus, underscored the devastating global impact of such spillovers. IDV’s emergence as a potential zoonotic threat adds another layer of complexity to an already strained public health landscape.

Several factors heighten concerns about IDV:

1. Widespread Circulation in Livestock

IDV has been detected in cattle herds across North America, Europe, and Asia. A 2024 study in Science found serological evidence of IDV exposure in up to 50% of cattle tested in some regions, suggesting the virus is far more prevalent than previously recognized. With global livestock populations in close contact with humans—through farming, slaughterhouses, and live animal markets—the opportunities for spillover are abundant.

2. Lack of Human Immunity

Unlike seasonal influenza viruses, which most humans encounter repeatedly over their lifetimes, IDV is novel to the human immune system. This lack of pre-existing immunity could allow the virus to spread rapidly if it gains the ability to transmit efficiently between people.

3. Potential for Reassortment

Influenza viruses are notorious for their ability to swap genetic material—a process called reassortment—when two different strains infect the same host. If IDV were to co-infect a human or animal with a human-adapted influenza virus, the resulting hybrid could possess a dangerous combination of high transmissibility and low immunity in the population.

What’s Next? Surveillance and Preparedness

The Ohio State University study concludes with a clear call to action: “Enhanced surveillance of IDV at the animal-human interface is critical to detect spillover events early and prevent a potential pandemic.” Public health agencies and researchers are now prioritizing several key steps:

1. Expanding Animal Surveillance

The U.S. Department of Agriculture (USDA) and the Centers for Disease Control and Prevention (CDC) are ramping up testing of cattle, pigs, and other livestock for IDV. This includes routine screening of animals exhibiting respiratory symptoms, as well as serological studies to track past exposure.

2. Monitoring Human Populations

While no confirmed human cases of IDV have been reported as of April 2026, the CDC is working with state health departments to monitor individuals with occupational exposure to livestock, such as farmers, veterinarians, and slaughterhouse workers. Symptoms to watch for include fever, cough, and respiratory distress—similar to those caused by other influenza viruses.

3. Developing Diagnostic Tools

Current diagnostic tests for influenza are not designed to detect IDV. Researchers are developing specific PCR assays and serological tests to identify the virus in both animals and humans. Rapid, accurate diagnostics will be essential for containing outbreaks before they spread.

4. Exploring Vaccine and Antiviral Options

While no IDV-specific vaccines or antivirals exist yet, researchers are investigating whether existing influenza vaccines or treatments (such as oseltamivir) might offer cross-protection. Early-stage research is also underway to develop a targeted IDV vaccine, though this could take years to bring to market.

Key Takeaways for the Public

• IDV is not currently a widespread threat to humans. While the virus can replicate in human cells, no sustained human-to-human transmission has been observed.
• Occupational exposure is the primary risk. Individuals who work closely with livestock should take precautions, such as wearing personal protective equipment (PPE) and practicing good hand hygiene.
• Surveillance is critical. Early detection of spillover events could prevent a larger outbreak. Public health agencies are scaling up monitoring efforts.
• Preparation is underway. Researchers are developing diagnostic tools, vaccines, and treatment strategies to respond quickly if IDV begins spreading among humans.

FAQ: What You Need to Know About Influenza D Virus

Q: How is IDV different from the flu I gain every year?

A: The seasonal flu is caused by influenza A and B viruses, which circulate widely in humans. IDV, is primarily a livestock virus. While it shares some similarities with other influenza viruses, it is genetically distinct and has not yet established itself in human populations.

Q: Should I be worried about catching IDV?

A: At this time, the risk to the general public is low. No human cases have been confirmed, and the virus does not appear to transmit easily between people. Yet, individuals with frequent contact with livestock should remain vigilant and follow recommended safety protocols.

Q: What are the symptoms of IDV in humans?

A: Because no human cases have been confirmed, the symptoms of IDV infection in humans are not well understood. Based on its behavior in animals, experts speculate that symptoms could resemble those of other influenza viruses, including fever, cough, sore throat, and body aches.

Q: Can IDV be treated with existing flu medications?

A: It’s unclear. Some antiviral drugs used to treat influenza A and B, such as oseltamivir (Tamiflu), may be effective against IDV, but this has not been definitively proven. Research is ongoing to determine the best treatment options.

Q: What can I do to protect myself?

A: For most people, standard flu prevention measures—such as getting an annual flu vaccine, washing hands frequently, and avoiding close contact with sick individuals—are sufficient. Those who work with livestock should wear PPE, such as masks and gloves, and follow biosecurity protocols to minimize exposure.

The Bottom Line

Influenza D virus represents a potential but not yet realized threat to human health. While the recent findings from The Ohio State University are concerning, they also provide an opportunity to act proactively. By expanding surveillance, developing diagnostic tools, and preparing countermeasures, public health officials aim to prevent IDV from becoming the next zoonotic pandemic.

For now, the message is clear: stay informed, follow public health guidance, and support efforts to monitor and contain emerging infectious diseases. The lessons of past pandemics have taught us that preparedness is the best defense—and when it comes to IDV, the time to prepare is now.